Literature DB >> 15165529

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

Wayne Hening1, Arthur S Walters, Richard P Allen, Jacques Montplaisir, Andrew Myers, Luigi Ferini-Strambi.   

Abstract

OBJECTIVES: To assess the frequency, impact, and medical response to the restless legs syndrome (RLS) in a large multi-national primary care population.
METHOD: Questionnaire surveys of matched patients and primary care physicians (PCPs) in five modern industrialized western countries.
RESULTS: An RLS screening questionnaire was completed by 23,052 patients: 2223 (9.6%) reported weekly RLS symptoms; 1557 of these patients had medical follow-up questionnaires completed both by themselves and by their physician. An RLS sufferer subgroup (n=551) likely warranting treatment was defined as reporting at least twice weekly symptoms with appreciable negative impact on quality of life. A total of 88.4% of RLS sufferers reported at least one sleep-related symptom. Most reported impaired sleep consistent with a diagnosis of insomnia. Out of 551 sufferers, 357 (64.8%) reported consulting a physician about their RLS symptoms, but only 46 of these 357 (12.9%) reported having been given a diagnosis. PCPs reported that 209 (37.9%) RLS sufferers consulted them about RLS symptoms, but only 52 (24.9%) were given an RLS diagnosis. In most countries, sufferers, regardless of diagnosis, were prescribed therapies not known to be effective in RLS.
CONCLUSIONS: RLS significantly impairs patients' lives, often by severely disrupting sleep. The marked under-diagnosis and inappropriate treatment of RLS indicates that PCPs need better education about this condition. Recognizing how often disrupted sleep results from RLS should improve diagnosis.

Entities:  

Mesh:

Year:  2004        PMID: 15165529     DOI: 10.1016/j.sleep.2004.03.006

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  116 in total

Review 1.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

Review 2.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

Review 3.  Update in restless legs syndrome.

Authors:  Rachel E Salas; Charlene E Gamaldo; Richard P Allen
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

4.  Restless legs syndrome due to aripiprazole.

Authors:  Juan Bolaños-Vergaray; Juan Carlos Obaya; Rafael Gonzalez; Cristina Echeverri; Pilar Piquer
Journal:  Eur J Clin Pharmacol       Date:  2010-11-21       Impact factor: 2.953

5.  Iron deficiency anemia in infancy exerts long-term effects on the tibialis anterior motor activity during sleep in childhood.

Authors:  Patricio Peirano; Cecilia Algarin; Rodrigo Chamorro; Mauro Manconi; Betsy Lozoff; Raffaele Ferri
Journal:  Sleep Med       Date:  2012-07-04       Impact factor: 3.492

6.  Nature and variants of idiopathic restless legs syndrome: observations from 152 patients referred to secondary care in the UK.

Authors:  R Holmes; S Tluk; V Metta; P Patel; R Rao; A Williams; K R Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2007-01-22       Impact factor: 3.575

Review 7.  [Iron deficiency, Fatigue and Restless-Legs-Syndrome].

Authors:  Bettina Wurzinger; Peter König
Journal:  Wien Med Wochenschr       Date:  2016-08-30

8.  Restless Legs Syndrome and Depression: Effect Mediation by Disturbed Sleep and Periodic Limb Movements.

Authors:  Brian B Koo; Terri Blackwell; Hochang B Lee; Katie L Stone; Elan D Louis; Susan Redline
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-27       Impact factor: 4.105

Review 9.  Ropinirole: for the treatment of restless legs syndrome.

Authors:  Susan M Cheer; Lynne M Bang; Gillian M Keating
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.

Authors:  Susan A VanMeter; Sarah T Kavanagh; Samantha Warren; Ronald W Barrett
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.